DMTX Dimension Therapeutics, Inc.

1.90
+0  (0%)
Previous Close 1.90
Open 1.90
Price To book 0.66
Market Cap 47.58M
Shares 25,043,000
Volume 96,689
Short Ratio 1.99
Av. Daily Volume 145,747

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated late 2016 - Announced December 13, 2016 that IND submission had been accepted by FDA.
DTX101
Ornithine Transcarbamylase (OTC) Deficiency
Phase 1/2 initial data released January 31, 2017.
DTX101
hemophilia B

Latest News

  1. Lifshitz & Miller LLP Announces Investigation of BT Group plc, Celadon Group, Inc., Community Health Systems, Inc., Dimension Therapeutics, Inc., Home Capital Group Inc., Lifevantage Corporation, OvaScience, Inc. and Under Armour, Inc.
  2. Newman Ferrara LLP Announces Corporate Governance Investigation of Dimension Therapeutics Inc.
  3. Cerner's EHR Platform to Enhance Health Care at San Juan NGO
  4. Dimension Therapeutics Elects Dr. John A. Hohneker to Its Board of Directors
  5. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Dimension Therapeutics, Inc.
  6. Dimension Therapeutics downgraded by Cantor Fitzgerald
  7. DIMENSION THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events
  8. Dimension Announces Interim Topline Results from Ongoing Phase 1/2 Clinical Program for DTX101, Dimension’s Lead AAV Product Candidate in Development for Adult Patients with Moderate/Severe to Severe Hemophilia B
  9. vTv Therapeutics (VTVT) in Focus: Stock Moves 6.7% Higher
  10. DIMENSION THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  11. Is Dimension Therapeutics Inc (DMTX) Going to Burn These Hedge Funds?
  12. Dimension Therapeutics Announces FDA Acceptance of Investigational New Drug Application for DTX301 to Treat OTC Deficiency
  13. Dimension Therapeutics Announces Presentation at the 58th American Society of Hematology (ASH) Annual Meeting
  14. Dimension Therapeutics Receives Positive Opinion for European Orphan Drug Designation of DTX401 for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
  15. DIMENSION THERAPEUTICS, INC. Financials
  16. Here’s What We Are Looking For From The Upcoming Dimension Therapeutics Inc (DMTX) Data
  17. ETFs with exposure to Dimension Therapeutics, Inc. : November 14, 2016
  18. Dimension Therapeutics, Inc. :DMTX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 11, 2016
  19. Dimension Therapeutics Reports Recent Corporate Progress and Third Quarter 2016 Financial Results
  20. DIMENSION THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements